197 related articles for article (PubMed ID: 36814351)
61. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
[TBL] [Abstract][Full Text] [Related]
62. Case report: Successful treatment of a patient with relapsed/refractory primary central nervous system lymphoma with thiotepa-based induction, autologous stem cell transplantation and maintenance.
Wang L; Fan Y; Chen B; Zhang J; Yang L; Qiu X; Jiang H; Li J; Xiao X; Huang L; Xu Y
Front Oncol; 2023; 13():1333761. PubMed ID: 38348121
[TBL] [Abstract][Full Text] [Related]
63. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
64. High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions.
Ferreri AJ; Crocchiolo R; Assanelli A; Govi S; Reni M
Leuk Lymphoma; 2008 Nov; 49(11):2042-7. PubMed ID: 19021047
[TBL] [Abstract][Full Text] [Related]
65. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
[TBL] [Abstract][Full Text] [Related]
66. Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.
Chamberlain MC
J Neurooncol; 2014 May; 118(1):155-62. PubMed ID: 24584709
[TBL] [Abstract][Full Text] [Related]
67. [Primary central nervous system lymphoma: advances in treatment strategies].
Kondo E
Rinsho Ketsueki; 2020; 61(5):510-519. PubMed ID: 32507817
[TBL] [Abstract][Full Text] [Related]
68. Is reduced-dose whole-brain radiotherapy also feasible in primary CNS lymphoma for curative or salvage purpose?
Ko MK; Kwak YK; Choi BO; Jeun SS; Park JS; Ahn S; Song JH
J Neurooncol; 2023 Nov; 165(2):321-328. PubMed ID: 37964132
[TBL] [Abstract][Full Text] [Related]
69. Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China.
Sun X; Wu Y; Xing R; Bai X; Qian J; Zhu H; Cui Q; Chen Y; Liu Q; Lai W; Li J; Wang Y; Sun S; Gao C; Ji N; Liu Y
Front Oncol; 2022; 12():792274. PubMed ID: 35280789
[TBL] [Abstract][Full Text] [Related]
70. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.
Jahnke K; Thiel E; Martus P; Herrlinger U; Weller M; Fischer L; Korfel A;
J Neurooncol; 2006 Nov; 80(2):159-65. PubMed ID: 16699873
[TBL] [Abstract][Full Text] [Related]
71. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.
Nguyen PL; Chakravarti A; Finkelstein DM; Hochberg FH; Batchelor TT; Loeffler JS
J Clin Oncol; 2005 Mar; 23(7):1507-13. PubMed ID: 15735126
[TBL] [Abstract][Full Text] [Related]
72. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
Kasenda B; Schorb E; Fritsch K; Finke J; Illerhaus G
Ann Oncol; 2012 Oct; 23(10):2670-2675. PubMed ID: 22473593
[TBL] [Abstract][Full Text] [Related]
73. High-dose methotrexate combined with rituximab improves the survival rate of patients with primary central nervous system lymphoma.
Fu J; Ma X
J BUON; 2021; 26(2):366-372. PubMed ID: 34076981
[TBL] [Abstract][Full Text] [Related]
74. Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis.
Yoon SE; Jo H; Kang ES; Cho D; Cho J; Kim WS; Kim SJ
Bone Marrow Transplant; 2022 Apr; 57(4):641-648. PubMed ID: 35173287
[TBL] [Abstract][Full Text] [Related]
75. Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma.
Kim JE; Yoon DH; Kim S; Lee DH; Kim JH; Yoon YH; Chi HS; Lee SW; Park CS; Huh J; Suh C
Korean J Hematol; 2012 Mar; 47(1):60-6. PubMed ID: 22479279
[TBL] [Abstract][Full Text] [Related]
76. Results of treatment of 112 cases of primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
[TBL] [Abstract][Full Text] [Related]
77. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
[TBL] [Abstract][Full Text] [Related]
78. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
[TBL] [Abstract][Full Text] [Related]
79. Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis.
Epperla N; Reljic T; Chowdhury SM; Ferreri AJM; Kumar A; Hamadani M
Hematol Oncol; 2023 Feb; 41(1):88-96. PubMed ID: 36192141
[TBL] [Abstract][Full Text] [Related]
80. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
